Synthetic promoter for modulating gene expression
View Patent ↗The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed using selected PDX-1 activation sites such as those observed in the human insulin promoter (HIP). In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide.
1. A nucleic acid comprising:
a BL promoter having at least three copies of a nucleotide sequence comprising nucleotide sequence motifs GG2, A2, C1, E1, A1 linked in an order: GG2/A2/C1/E1/A1, wherein:
GG2 comprises GGAAAT (SEQ ID NO: 9);
A2 comprises GGAAAT (SEQ ID NO: 10);
C1 comprises TGCAGCCTCAGCC (SEQ ID NO: 11);
E1 comprises GCCATCTGCC (SEQ ID NO: 12);
A1 comprises TAAT (SEQ ID NO: 13);
the nucleotide sequence motifs are separated by 0 to 20 nucleotides;
the BL promoter modulates transcription of an heterologous nucleic acid operatively linked to the BL promoter.
2. The nucleic acid of claim 1 , wherein the BL promoter further includes at least one nucleotide sequence comprising C2, E2, G2, A3, CRE1, CRE2, CRE3, G1 or an enhancer core, wherein:
C2 comprises CAGGGACAGG (SEQ ID NO: 6);
E2 comprises GCCACCGG (SEQ ID NO: 7);
G2 comprises GGGCCC (SEQ ID NO: 8);
A3 comprises TAAT (SEQ ID NO: 13);
CRE1 comprises GACCCGCTGGTCC (SEQ ID NO: 16);
CRE2 comprises TGACGACCAAGGAGATC (SEQ ID NO: 17);
CRE3 comprises TGCATCAGAAGAG (SEQ ID NO: 18);
CRE4 comprises TGCGTCAGGTGGGCT (SEQ ID NO: 19);
G1 comprises GTAGGGGA (SEQ ID NO: 15); and
the enhancer core comprises TGGAAAG (SEQ ID NO: 5).
3. The nucleic acid of claim 2 , wherein the BL promoter comprises:
a BL-1 promoter as shown in SEQ ID NO: 1; or
a BL-4 promoter as shown in SEQ ID NO: 3.
4. A nucleic acid comprising:
a BL promoter having at least three copies of a nucleotide sequence comprising nucleotide sequence motifs GG2, A2, C1, E1, A1 linked in an order: GG2/A2/C1/E1/A1, wherein:
GG2 comprises GGAAAT (SEQ ID NO: 9);
A2 comprises GGAAAT (SEQ ID NO: 10);
C1 comprises TGCAGCCTCAGCC (SEQ ID NO: 11);
E1 comprises GCCATCTGCC (SEQ ID NO: 12);
A1 comprises TART (SEQ ID NO: 13);
the nucleotide sequence motifs are separated by 0 to 20 nucleotides;
the BL promoter modulates transcription of an heterologous nucleic acid operatively linked to the BL promoter; and
a heterologous nucleic acid operatively linked to the BL promoter, wherein the heterologous nucleic acid encodes a polypeptide sequence.
5. An expression vector comprising the nucleic acid of claim 1 .
6. A host cell comprising the vector of claim 5 .
7. The host cell of claim 6 wherein the cell is an Escherichia coli , yeast or human cancer cell.
8. A composition of matter comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.
9. A nucleic acid comprising a BL-1 promoter as shown in SEQ ID NO: 1.
10. The nucleic acid of claim 9 , wherein the BL-1 promoter is operatively coupled to a heterologous nucleic acid sequence.